Dr. Sundar Jagannath MD Medical Oncologist

Dr. Sundar Jagannath is a medical oncologist in New York, New York. He is affiliated with multiple hospitals in the area, including Mount Sinai Hospital and Mount Sinai Medical Center. He received his medical degree from Baroda Medical College and has been in practice for 31 years. He is one of 38 doctors at Mount Sinai Hospital and one of 9 at Mount Sinai Medical Center who specialize in Medical Oncology.

Are you Dr. Sundar Jagannath? Claim your profile to make edits or add details. Claim/Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: General Oncology

Hospital Affiliation

Mount Sinai Medical Center

Mount Sinai Hospital
High performing in Cancer

Education & Medical Training

Wayne State University School of Medicine
Residency, Internal Medicine, 1979 - 1980

Bronx-Lebanon Hospital Center
Residency, Internal Medicine, 1977 - 1979

University of Texas M D Anderson Cancer Center
Residency, Internal Medicine, 1980 - 1982

Baroda Medical College
Class of 1976

Certifications & Licensure

American Board of Internal Medicine
Certified in Internal Medicine

American Board of Internal Medicine
Certified in Medical Oncology

MI State Medical License
Active through 2014

NY State Medical License
Active through 2013

Publications & Presentations

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
Mulligan, G.,Lichter, D. I.,Di Bacco, A.,Blakemore, S. J.,Berger, A.,Koenig, E.,Bernard, H.,Trepicchio, W.,Li, B.,Neuwirth, R.,Chattopadhyay, N.,Bolen, J. B.,Dorner, A. J.,van de Velde, H.,Ricci, D.,Jagannath, S.,Berenson, J. R.,Richardson, P. G.,Stadtmauer, E. A.,Orlowski, R. Z.,Lonial, S.,Anderson, K. C.,Sonneveld, P.,San Miguel, J. F.,Esseltine, D. L.,Schu, M.

A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma.
Chepovetsky, J.,Chari, A.,Jagannath, S.,Ramanthan, L.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.
Jakubowiak, A. J.,Siegel, D. S.,Martin, T.,Wang, M.,Vij, R.,Lonial, S.,Trudel, S.,Kukreti, V.,Bahlis, N.,Alsina, M.,Chanan-Khan, A.,Buadi, F.,Reu, F. J.,Somlo, G.,Zonder, J.,Song, K.,Stewart, A. K.,Stadtmauer, E.,Harrison, B. L.,Wong, A. F.,Orlowski, R. Z.,Jagannath, S.

See all 12 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • BCBS Blue Card PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • Empire BCBS HMO
  • Empire BCBS PPO
  • GHI PPO
  • Great West PPO
  • HIP of New York - Select PPO
  • Humana ChoiceCare Network PPO
  • MagnaCare PPO
  • Multiplan PHCS PPO
  • Multiplan PPO
  • MVP Healthcare PPO
  • Oxford Health Freedom
  • Oxford Health Liberty
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by

Specialty

Location

Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.